Compliance or Creativity: What Should MLR Teams Prioritize for Better Outcomes?

In the highly regulated world of healthcare communications, Medical, Legal, and Regulatory (MLR) review teams walk a fine line between ensuring compliance and enabling creativity. The challenge lies in maintaining scientific and regulatory rigor without stifling innovation or agility.

This dilemma was the focus of a recent Indegene Digital Summit [Virtual Edition] moderated by Robert Leibman, who leads the MLR service line within Indegene’s Enterprise Medical Solutions team. Joining him were Carlyn Martina-Mamber, Head of Medical Communications at Lantheus, and Pankaj Chandak, Director of Regulatory Affairs at Medtronic. Together, they explored how MLR teams can evolve to better balance compliance with creativity while maintaining trust, efficiency, and integrity.

Balancing compliance and creativity often starts with how organizations perceive and manage risk. In the pursuit of accuracy, many MLR teams tend to build highly controlled systems and processes that prioritize caution over speed. While this ensures consistency, it can also lead to inefficiencies and hinder timely scientific communication. Finding the right level of structure without constraining innovation has therefore become an important discussion across the industry.

The panel agreed that MLR is “more of an art than a science.” Striking the right balance between accuracy and agility often comes down to how well organizations define their risk appetite and align around it. Over-engineering the process can slow content delivery, while too much flexibility can introduce risk.

Pankaj Chandak noted that achieving this balance requires ensuring content remains compliant while still meeting business needs. Teams are often required to navigate grey areas where regulations are not prescriptive, and interpretations must be applied responsibly to maintain both accuracy and agility.

A risk-based approach emerged as a key theme that recognizes not all materials carry the same level of scrutiny. Instead of applying identical review depth to every asset, teams should tailor workflows based on content type, regulatory sensitivity, and business urgency. Building this flexibility, the speakers noted, enables speed without compromising quality.

As the life sciences industry adopts more digital tools, AI risk assessment and AI risk mitigation are becoming integral to pharma risk management. These capabilities can help MLR and regulatory teams identify potential compliance gaps earlier, predict review bottlenecks, and make data-driven decisions that improve both consistency and agility.

True innovation in MLR does not start with technology. It starts with collaboration. When teams work in silos or lack a shared understanding of objectives, friction naturally arises.

Carlyn highlighted that alignment should begin with strategic imperatives, cascade to project goals, and ensure that every stakeholder, including medical, legal, regulatory, and marketing, shares the same vision of success.

When reviewers and content creators view each other as partners rather than adversaries, creativity flourishes. This mindset shift allows organizations to play offense, enabling faster, more confident decision-making across the MLR process.

Beyond collaboration itself, communication cadence also plays a crucial role. Establishing consistent touchpoints between cross-functional teams, particularly during early content planning, can help pre-empt challenges that often surface later in the review cycle. As one takeaway from the panel suggested, collaboration must be proactive, not reactive, with shared visibility into priorities, timelines, and success metrics that connect the efforts of every function involved in MLR.

Artificial Intelligence (AI) is rapidly transforming how MLR teams review and manage content. From automating reference checks and AI risk assessment to enhancing content modularization, AI offers clear opportunities to improve both efficiency and accuracy.

In addition to improving operational efficiency, AI in Regulatory Affairs is helping organizations identify potential compliance issues before they escalate. Automated tagging, data validation, and evidence traceability are becoming key enablers of faster and more reliable reviews. Similarly, AI in Medical Affairs supports consistent message alignment and scientific accuracy across channels.

Rather than replacing human expertise, AI should be seen as an enabler, freeing reviewers from manual effort so they can focus on strategic, high-value decisions. The most impactful outcomes occur when humans leverage AI as a collaborator rather than a substitute.

The panel agrees that even with advanced tools and processes, success ultimately depends on organizational culture. A culture grounded in collaboration, transparency, and shared accountability ensures that technology and process improvements take root. Teams that embrace learning, trust, and cross-functional empathy are better positioned to balance compliance with creative excellence.

In many ways, culture is the true foundation of effective pharma risk management. Technology may help identify risks, but it is the mindset of openness, trust, and shared accountability that determines whether those insights translate into sustainable improvement.

The panel closed with a simple message: balancing compliance and creativity is not about loosening controls. It is about building alignment and trust across every function involved in content review.

Organizations that define clear boundaries of risk, embrace collaboration, and nurture a culture of trust can move from being reactive gatekeepers to proactive enablers of innovation.

In the end, creativity does not compete with compliance. It thrives when compliance is grounded in partnership and purpose.